GGrantIndex
← Leaderboards

Ryan Dee Ross

Rush University Medical Center

$5,489,107
Attributed
$10,282,749
Total exposure
7
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.8M · FY201925
$5M$3.8M$2.5M$1.3M$0
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$10,282,749 · 7

By mechanism

U01$5,980,971 · 1
R01$2,949,269 · 2
R03$486,900 · 2
K01$461,546 · 1
R21$404,063 · 1

Most similar at Rush University Medical Center

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Bone

Research focus

BoneSkeletalOsteoporosisAffectMouse ModelBone MassResponseTissuesResearch PersonnelReportingCellsHormonesProductionTreatment StrategyInterestAntiretroviral TherapyPre-ClinicalAnimal ModelFundingIn VitroOsteogenesisSamplingChronic DiseasePersons

Grant awards (18)

MACS/WIHS Combined Cohort Study: Cook County Clinical Research Site (CC_CRS)$3,000,561
U01 · FY2025 · HL
Bone and fat cross-talk in antiretroviral therapy (ART) treated HIV patients$364,953
R01 · FY2025 · AR · contact PI
How bisphosphonates affect bone matrix and remodeling: implications for atypical femoral fractures$353,132
R01 · FY2025 · AR · contact PI
MACS/WIHS Combined Cohort Study: Cook County Clinical Research Site (CC_CRS)$2,980,410
U01 · FY2024 · HL
Bone and fat cross-talk in antiretroviral therapy (ART) treated HIV patients$393,338
R01 · FY2024 · AR · contact PI
How bisphosphonates affect bone matrix and remodeling: implications for atypical femoral fractures$391,487
R01 · FY2024 · AR · contact PI
How bisphosphonates affect bone matrix and remodeling: implications for atypical femoral fractures$464,873
R01 · FY2023 · AR · contact PI
Bone and fat cross-talk in antiretroviral therapy (ART) treated HIV patients$388,039
R01 · FY2023 · AR · contact PI
Bone and fat cross-talk in antiretroviral therapy (ART) treated HIV patients$175,644
R01 · FY2023 · AR · contact PI
Identifying the long-term metabolic complications of in-utero and lactational antiretroviral exposure$158,000
R03 · FY2023 · HD · contact PI
Bone and fat cross-talk in antiretroviral therapy (ART) treated HIV patients$417,803
R01 · FY2022 · AR · contact PI
Assessing the function role of sclerostin in periodontal disease in XLH$161,373
R03 · FY2022 · DE · contact PI
Sclerostin Regulation of Skeletal Mineralization and Phosphate Metabolism$86,993
K01 · FY2022 · AR · contact PI
Characterization of a humanized mouse model to study HIV and ARV effects on bone$404,063
R21 · FY2021 · AR · contact PI
Assessing the function role of sclerostin in periodontal disease in XLH$167,527
R03 · FY2021 · DE · contact PI
Sclerostin Regulation of Skeletal Mineralization and Phosphate Metabolism$124,851
K01 · FY2021 · AR · contact PI
Sclerostin Regulation of Skeletal Mineralization and Phosphate Metabolism$124,851
K01 · FY2020 · AR · contact PI
Sclerostin Regulation of Skeletal Mineralization and Phosphate Metabolism$124,851
K01 · FY2019 · AR · contact PI